“This is common sense legislation that provides physicians, not lawmakers, the ability and discretion to decide what treatment options are best for their patients.”
Paul Armentano NORML Deputy Director
Posts by 'Paul Armentano NORML Deputy Director'
The Centers for Disease Control and Prevention is still seeking public comments on how Americans with chronic pain are successfully treating their symptoms. The deadline to submit comments to the agency is Tuesday, June 16, 2020.
The proposed measure expands the discretion of physicians so that they can recommend cannabis therapy for “any condition” that he or she “considers debilitating to an individual patient and is qualified through his [or her] medical education and training to treat.”
“This feasibility trial demonstrated that a metered-dose cannabis inhaler delivered precise and low THC doses [that] produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/complex-regional pain syndrome.”
In his veto message, the Governor wrote: “The language in the bill makes substantial policy changes to the medical marijuana program that were not fully scrutinized through normal legislative procedures before the bill was received by my office in the middle of the night Saturday. While there is much room for improvement in the way our state’s program operates, this bill does not address those items in a way I can support.”
“To our knowledge, this is the first study examining the effect of recreational legalization of marijuana in the US on adolescent treatment admissions for marijuana use. Our results indicate that RML in Colorado and Washington was not associated with an increase in treatment admissions. Rather, we observe a substantial decline in admissions rates across US states.”
“[L]egalization in Colorado is associated with an increase of nearly 51,000 hotel rooms rented per month [and] once commercial sale is permitted, there is an increase of almost 120,000 room rentals per month.”
House lawmakers have overwhelmingly passed a pair of bills to better expand and facilitate access to medical cannabis products.
The legislation, if enacted, would have shielded an estimated 200,000 low-level marijuana convictions from public view.
“Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.”
